Ketanov (Ketorolac Trometamol)

Ketorolac trometamol works by non‑selectively inhibiting the cyclooxygenase enzymes COX‑1 and COX‑2, which blocks the conversion of arachidonic acid to prostaglandins. The reduction in prostaglandin synthesis decreases peripheral sensitisation of nociceptors and limits inflammation, providing analgesic and antipyretic effects.

The specific dose of Ketanov is determined by the prescribing clinician based on the patient’s condition, weight, renal function and the intended route of administration. Dosing recommendations are provided in the product’s prescribing information and must be followed by a qualified health‑care professional.

Safety data for ketorolac trometamol in pregnancy and lactation are limited. It is generally avoided in the third trimester because of potential effects on fetal renal function and ductus arteriosus closure. Breast‑feeding mothers should consult a health‑care provider before use, as the drug may be excreted in milk.

To request Ketanov, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with many oral NSAIDs, ketorolac provides a more rapid and potent analgesic effect when given by injection, making it suitable for acute severe pain. However, its risk profile for gastrointestinal bleeding, renal impairment and cardiovascular events is similar to other non‑selective NSAIDs, so risk‑benefit assessment remains essential.

Ketanov should be stored at room temperature, below 25 °C, in its original packaging. It must be protected from moisture and direct light. Unused vials should be kept sealed until use, and any reconstituted solution should be administered promptly according to the product label.

Ketanov is supplied as an injectable solution for intramuscular or intravenous administration. The injection is performed by a qualified health‑care professional using aseptic technique. The specific route, volume and rate of injection are determined by the prescriber based on the clinical situation.

The most serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe hypersensitivity reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke. Patients with a history of peptic ulcer disease, renal impairment or cardiovascular disease require careful monitoring or may need alternative therapy.

Ketanov is contraindicated in patients with known hypersensitivity to ketorolac or other NSAIDs, those with active gastrointestinal bleeding or ulceration, severe renal impairment, and in the peri‑operative setting for coronary artery bypass graft surgery. It should also be avoided in the third trimester of pregnancy.